BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price objective on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

BLRX stock opened at $0.27 on Friday. BioLineRx has a 52-week low of $0.19 and a 52-week high of $1.58. The business has a fifty day moving average of $0.32 and a two-hundred day moving average of $0.52. The stock has a market cap of $21.89 million, a price-to-earnings ratio of -1.24 and a beta of 1.39. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11.

Institutional Trading of BioLineRx

Institutional investors have recently added to or reduced their stakes in the stock. Atria Investments Inc boosted its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the period. PVG Asset Management Corp acquired a new position in BioLineRx during the 2nd quarter worth about $70,000. Finally, CVI Holdings LLC purchased a new position in BioLineRx during the 2nd quarter valued at about $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.